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Distribution of Prolyl Oligopeptidase in Human Peripheral Tissues
and Body Fluids1)
Filip Goossens, Ingrid De Meester, Greet Vanhoofmd Simon Schärpe
Laboratorium voor Modische Biochemie, Universiteit Antwerpen (UIA), Wilrijk, Belgium
Summary: Prolyl oligopeptidase (EC 3.4.21.26) activity was measured in human tissue homogenates and body
fluids. The enzyme was ubiquitously present, revealing high activity in renal cortex, epithelial cells, fibroblasts,
testis, lymphocytes and thrombocytes. The activity in the body fluids was low. Prolyl oligopeptidase activity was
significant higher in tumours of prostate, lung and sigmoid, than in the healthy tissues. Sera of individuals suffering
from HIV infection, malaria, prostate cancer or benign prostate hypertrophy contained lowered activity. Interest-
ingly, the low serum activity during prostate carcinoma increased upon medical treatment with anti-androgens. This
suggests hormonal control of the gene transcript. A positive correlation with angiotensin converting enzyme activity
in hypertensive patients was demonstrated and this further supports the possible involvement of prolyl oligopepti-
dase in the renin-angiotensin system and in the pathogenesis of hypertension.
Introduction
Proline occupies a special position among the 20 dif-
ferent amino acids. Being the only cyclic amino acid, its
rigid structure imposes several constraints on a peptide
bond. The presence of an imino instead of an amino
group prevents the amino acid from forming hydrogen
bonds. Furthermore, the cyclic structure decreases the
energy difference between the cis and the trans confor-
mation, so that a larger percentage of X-Pro bonds sup-
ports the cis conformation rather than the ail-trans con-
formation. On account of these factors, peptide bonds
involving proline are seldom cleaved by classical serine
endopeptidases, since they hardly fit in the active site
(1). Within any protein, proline residues therefore gen-
erally represent sites that are resistant to proteolytic
cleavage (2).
Prolyl oligopeptidase (post proline cleaving enzyme,
prolyl endopeptidase)2) is the only proline specific en-
dopeptidase presently known in mammals (3). The en-
zyme was discovered by Walter and colleagues (4) as an
oxytocin degrading enzyme. It cleaves peptides at the
carboxyl side of proline if this amino acid is preceded
by at least two residues (5). This cytosolic serine endo-
peptidase has been purified from bacterial sources (6)
and human tissues (7). Since the enzyme can only hy-
drolyse small peptides (8) it is thought to be involved in
') Funds: Nationaal Fonds voor het Wetenschappelijk Onderzoek
en Interuniversitaire Attractiepolen. Dr. /. De Meester and Dr. G.
Vanhoofwt senior research assistants of the Nationaal Fonds voor
het Wetenschappelijk Onderzoek.
2) Enzymes:
Angiotensin converting enzyme (EC 3.4.15.1)
Prolyl oligopeptidase (EC 3.4.21.26)
the metabolism of neuropeptides. Indeed, peptides like
oxytocin, bradykinin, substance P and angiotensin (7)
are substrates of the enzyme. Although its substrate
specificity is well documented, the physiological role of
prolyl oligopeptidase remains unclear. We demonstrated
that the serum enzyme activity correlates with the dif-
ferent stages of depression (9), and Yoshimoto provided
evidence that inhibitors of the enzyme can prevent sco-
polamine-induced amnesia (10).
The sequence of the human enzyme was established (11)
and no homology was found with peptidases of known
structure. Prolyl oligopeptidase is a member of the fam-
ily of the oligopeptidases, a new class of enzymes with
specificity limited to small peptides (7, 12).
It was the aim of this work to determine the specific
activity of prolyl oligopeptidase in several human tis-
sues. The enzyme was present in several tumour tissues,
and serum prolyl oligopeptidase activity was altered in
a number of pathological conditions. Increasing evi-
dence that prolyl oligopeptidase participates in the re-
nin-angiotensin system also justifies the investigation of
its activity in hypertensive individuals (13).
Materials and Methods
Materials
The synthetic substrates used for the determination of prolyl oligo-
peptidase and angiotensin converting enzyme were obtained from
Bachern (Bachern, Bübendorf, Switzerland). The inhibitor Z-thio-
proline-thioprolinal was kindly provided by Dr. Kato* Yakult Co.
(Yakult Honsha, Furudai, Japan). All other reagents were of analyti-
cal grade and were purchased from Merck (Merck, Darmstadt, Ger-
many). The fluorimcter was from Shimadzu (Shimadzu Europe,
Köln, Germany). The centrifuge was from Beckman (Beckman In-
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strumcnts, M nchen, Germany). The reagent for (he protein deter-
mination was obtained from Pierce (Pierce ChemicaJ Co., Rock-
ford, IL, USA).
Body f l u i d s
Blood, urine and sperm were obtained from apparently healthy do-
nors. The prostatic fluids were obtained from vasectomized per-
sons. Pathological sera were obtained from the University Hospi-
tal, Antwerp.
Blood samples were centrifugcd at 900 g for 10 min and the serum
was stored at -20 °C.
Tissues
The different tissues were obtained by open surgery. Except when
especially stated, only those parts not involved in the disease status
were used. Prostatectomy was performed in patients with prostatic
carcinoma and benign prostatic hypertrophy. Normal prostate tissue
was acquired from patients with bladder cancer. All tissues were
washed with cold saline and stored as soon as possible in liquid
nitrogen, and kept frozen at -80°C. Tissue homogenates were
prepared by grinding the tissues in a Potter-Elvejhem homogenizer
either with one drop of Nonidet P40 per 200 mg of tissue, or by
the method of Lazo & Quinn (14), using a 30 mmol/1 solution of
octyl- -D-glucopyranoside. After centrifiigation at 50 000 g for 30
min at 4 °C the supernatant was stored at -80 °C until measure-
ment of the enzymatic activity and protein content. Vero-cells
(monkey kidney tumour), melanoma cells, fibroblasts, endothelial
cells, epithelial cells and breast tumour cells were obtained from
monolayer cultures. They were washed analogously but the solubi-
lization was performed by adding 10 ml/1 Triton X-100 and centri-
fiigation at 100 000 g at 4 °C for 60 min.
Differential centrifugation of seminal plasma
Seminal plasma was centrifuged at 900 g for 10 min at 4 °C in a
MSE Hl-spin 21 centrifuge, resulting in a supernatant and a pellet
containing the spermatozoa. The supernatant was centrifuged at
105 000 g for 120 min at 4 °C in a Beckman ultracentrifuge model
L350 to precipitate the prostasomes. The supernatant contains the
seminal fluid. The spermatozoan and prostasomal pellets were re-
suspended in parallel in 20 mmol/1 Tris, pH 7.4, 10 ml/I Triton Χ-
Ι 00, and centrifuged at 40 000 g for 20 min at 4 °C.
Angiotensin convert ing enzyme determination
Angiotensin converting enzyme was determined using 3-(2-ruryl-
acryloyl)-phenyl-glycyl-glycine as substrate and measuring the ab-
sorbance at 340 nm in a Cobas-Bio centrifugal spectrophotometric
analyser (Roche, Basel, Switzerland) according to Neels et al. (15).
Protein determination
Protein concentrations were determined by the bi-cinchoninic acid
detection reagent from Pierce. The protocol was followed accord-
ing to the manufacturer. Bovine serum albumin was used as a stan-
dard.
Enzyme assay
After thawing, the samples were centrifuged in an Eppendorf
centrifuge at 10000 min~! for 10 min at 4 °C. The supernatant
was used for the measurements. Prolyl oligopeptidase activity was
determined using the fluorogenic substrate N-benzyloxycarbonyl-
glycyl-prolyl-7-amino-4-methylcoumarin (Z-Gly-Pro-NHMec). 7-
Amino-4-methylcoumarin was used as the standard. The substrate
was dissolved in dimethylsulphoxide at a concentration of 5.6
mmol/1.
A 10 μΐ sample was incubated in 100 μΐ assay buffer (100 mmol/1
K2HP04, KH2PO4, pH 7.5 containing 1 mmol/1 dithiothreitol,
1 mmol/1 NaN3 and 1 mmol/1 EDTA) at 37 °C. After equilibration
for 3 min, 5 μΐ substrate were added. The assay was stopped after
20 min by the addition of 500 μΐ acetic acid (1.5 mol/1). The fluo-
rescence was measured at Xcx 370 and Xcm 440 nm, slidwidth 1.5
nm. All tissue samples were determined according to this protocol.
The body fluids were determined analogously, but they were incu-
bated for 120 min at 37 °C prior to addition of the stop solution
(16).
I n h i b i t i o n f
//-Benzyloxycarbonyl-thioprolyl-thioproiinal was dissolved in
methanol (stock 10 mmol/1). After the addition of inhibitor to a
final concentration of 100 nmol/1, the mixture with enzyme in as-
say buffer contained 3 ml/1 methanol. The enzyme was preincu-
bated at 37 °C for 20 min after which the residual activity was
determined by the addition of 5 μΐ substrate. A control experiment
was performed to determine the influence of the solvent (metha-
nol).
Results
Tissue distribution
Prolyl oligopeptidase was found to be distributed ubi-
quitously. The low levels present in the human body
fluids correspond to previous reports (16-18). Prolifer-
ating tissues revealed enhanced activity. Figure 1 shows
the enhanced prolyl oligopeptidase activity for malig-
nancies of lung (13.4 vs. 5.1 U/g), prostate (hypertro-
phy; 23.3 vs. 4.1 U/g), prostate (cancer; 6.4 vs. 4.1 U/g)
and sigmoid (carcinoma; 34.1 vs. 4.0 U/g). The addition
of 100 μΐ Z-thiopro-thioprolinal abolished all activity,
confirming that prolyl oligopeptidase was responsible
for the activity measured. Vero-cells, monkey kidney tu-
mour cells, contain the highest activity (36.7 U/g). These
latter cells also display higher activity than that found
in human renal tissue, but this may be a reflection of
the difference between species, which could obscure the
interpretation of this result. The enzyme activity in the
renal cortex is 45 times higher than in the medulla (fig.
1). This renal distribution parallels that of angiotensiii
converting enzyme (19) and dipeptidyl peptidase IV
(20). The results confirm that both lymphocytes and
thrombocytes are suitable sources for studies on human
prolyl oligopeptidase, including characterization and pu-
rification of the protein (7) and exploration the gene
(12).
Prolyl oligopeptidase in pathological sera
Investigation of pathological sera demonstrates a de-
creased enzymatic activity in sera of patients suffering
from HIV infection, malaria, benign prostate hypertro-
phy and prostate cancer (fig. 2). Interestingly, patients
affected by prostate cancer reveal enhanced prolyl oligo-
peptidase activity if treated with anti-androgens.
It was proven that the serum prolyl oligopeptidase level
of healthy persons varies within narrow margins (16)
and exhibits seasonal fluctuations (21). The origin of
serum prolyl oligopeptidase is still -unknown. It can be
calculated that the total activity of prolyl oligopeptidase
circulating in serum equals 2.3 U. Prolyl oligopeptidase
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is not secreted from cells so it only can enter the serum
compartment due to cell leakage or cell lysis. Five litres
of human blood contain approximately 1.5 X 1012 plate-
lets, accounting for 2580 mg platelet protein (22). Since
the specific activity of the platelets is 9 mU/mg this
means that the platelets contain approximately 24 U pro-
lyl oligopeptidase. This is 10 times the amount present
in serum. Platelets, together with the endothelial cells,
might be the source of the serum enzyme. Because of
the low activity measured in the liver, the contribution
of this tissue to the circulating prolyl oligopeptidase can
be neglected.
The prolyl oligopeptidase activity was measured in 19
untreated renal hypertensive patients. The results show
a significant positive correlation between serum angio-
tensin converting enzyme and prolyl oligopeptidase
(n = 19, r = 0.727, p < 0.001) (fig. 3). In view of the
suggested involvement of prolyl oligopeptidase in the
renin-angiotensin cascade and the in vivo metabolism by
this enzyme of peptides participating in the blood pres-
sure, this correlation supports the possible importance of
this enzyme in the aetiology of hypertension (13).
Discussion
A major finding of this study is the elevated level of
prolyl oligopeptidase in tumour tissues (fig. 1). This may
indicate participation of the enzyme in the cell cycle and
its up-regulation during stress conditions. Our results
correspond to reports of other groups (23-25), who de-
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Fig. 1 Screening of prolyl oligopeptidase in tissue extracts, body
fluids and several cell cultures.
All biological samples are of human origin, except the heart endo-
thelial cells which are of porcine origin, and the vero-cells which
are cultured monkey kidney tumour cells. The X-axis displays the
specific activity in U/g protein. Each bar gives the mean value and
the range of enzymatic activity.
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monstrated enhanced activity of this enzyme in regener-
ating tissues after injury. It is not known whether this
enhanced activity in malignant tissues results from an
interaction at die protein level, or has a genetic back-
ground. Specific and biocompatible inhibitors for prolyl
oligopeptidase should prove valuable in determining
whether this enzyme is related to the process of malig-
nancy.
The lack of correlation between the enhanced prolyl oli-
gopeptidase activity in prostate pathologies (fig. 1) and
the corresponding serum activity (fig. 2) indicates that
alterations of the tissue enzyme are not reflected in the
body fluids. It therefore appears impracticable to use se-
rum prolyl oligopeptidase as a tumour marker.
Treatment of patients suffering from prostate carcinoma
with anti-androgens results in the restoration of the se-
rum prolyl oligopeptidase activity, suggesting that a hor-
monal component, possibly a steroid, is regulating the
enzyme activity. This is in accordance with the reports
of Yasuda et al. (26) who found increased prolyl oligo-
peptidase activity after cortisol administration to human
placenta tissue culture. Ohta reported elevated prolyl
oligopeptidase activity following addition of progester-
one or oestradiol to ov riectomized mice. Intact mice
showed a variation of prolyl oligopeptidase activity dur-
ing the menstrual cycle, exhibiting a maximum at estrus
and a minimum at diestrus (27). Interestingly, Fransen
et al. isolated a cytosolic MT 80 000 protein which cross-
reacted with antibodies against hsp90 (Mr 90000 heat
shock protein), which is an intracellular steroid receptor,
and identified it as prolyl oligopeptidase (28). The serum
prolyl oligopeptidase activity correlates with serum an-
giotensin converting enzyme in hypertensive individuals
Control
HTV infection
Malaria infection
Campylobacter infection
Benign prostate hypertrophy
Prostate carcinoma
Prostate carcinoma(hormonally treated)
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Fig. 2 Prolyl oligopeptidase activity in pathological sera. tile. The results were analysed with the Student t-test. The asterix
Each bar represents the mean and the range of the enzymatic activ- (*) indicates a p< 0.01 and the double asterix (**) means the sta-
ity determined. In boldface are indicated the 10th and 90th percen- tistical significance is 0.01 < p < 0.05.
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Fig. 3 Correlation of the prolyl oligopeptidase and angiotensin the y-axis shows the serum angiotensin converting enzyme activity
converting enzyme activity in sera of patients affected by renovas- in U/l. The correlation coefficient is. 0.727 and is significant
cular hypertension. (p < 0.001).
The x-axis displays the prolyl oligopeptidase activity in U/l and
Goossens et al.: Distribution of human prolyl oligopeptidase 21
(fig. 3) and the renal distribution equals that of angioten-
sin converting enzyme. The lower activity in the me-
dulla might be interpreted with respect to the pharmacol-
ogy of vasopressin, a substrate of prolyl oligopeptidase.
Vasopressin exerts its potent antidiuretic effect in the
medulla, and inactivation by prolyl oligopeptidase could
result in excessive diuresis leading to dehydratation. In
view of the similarity in substrates, e.g. angiotensin
peptides and bradykinin, and renal distribution, the cor-
relation demonstrated in this study points to a participa-
tion of prolyl oligopeptidase in the renin-angiotensin
system and blood pressure management. The hyperten-
sive effect of angiotensin converting enzyme, through
its generation of angiotensin II and the metabolism of
bradykinin, might be amplified by the concomitant rise
in prolyl oligopeptidase activity. Like angiotensin con-
verting enzyme, prolyl oligopeptidase rapidly inactivates
bradykinin. Prolyl oligopeptidase converts both angio-
tensin I and II to angiotensin (1—7) as already demon-
strated in vitro (29) and in in vivo models (30, 31). This
peptide has vasodilator activity by the release of vasodi-
lator prostaglandins, prostaglandin E2 and 6-oxo-prosta-
glandin Fla (32). However, angiotensin (1—7) causes
coronary vasoconstrictions and it liberates vasopressin
after central administration (33). With respect to the cor-
onary actions, it is remarkable to note the high prolyl
oligopeptidase activity present in porcine heart endothe-
lium. This level is 5 times higher than in human placenta
endothelium. Interestingly, spontaneous hypertensive
rats contain enhanced amounts of angiotensin (1—7), the
product of prolyl oligopeptidase action (34). In addition
it was shown that bilateral nephrectomy in dogs
decreases the serum angiotensin (1—7) content 10 times,
indicating a renal origin of this peptide (35).
In summary, prolyl oligopeptidase activity was found to
be distributed in all body tissues and fluids, although the
activities in body fluids were lower than in the tissues.
The elevated activity of prolyl oligopeptidase in tumour
tissues suggests that it has a role in cell cycle control.
The upregulation of serum prolyl oligopeptidase activity
during treatment with anti-androgens suggests a possible
hormonal control of enzyme activity. Our results on the
parallel rise of prolyl oligopeptidase and angiotensin
converting enzyme in renal hypertension need to be fur-
ther explored in patients with hypertension of different
aetiology.
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